Let’s talk about risk, reward, and pennies. The three are of course related. There is no reward in the stock market without taking some risk – and penny stocks offer investors an optimal combination of both. The “pennies” are the cheapest stocks in the public markets, typically selling for less than $ 5 per share. With a stock price this low, even a small profit – an increase in the stock price by just a few cents – can quickly lead to a high percentage return. However, there is one but here. The critics point out that there could be a reason for the low price, whether it be poor fundamentals or overwhelming headwinds. So how are investors supposed to determine which penny stocks are ready to make them big? Tracking the activity of the investing titans is one strategy. Step into Israel “Izzy” Englander, well known for his formidable stock picking skills. Englander showed an interest in the stock market since his youth and founded the hedge fund Millennium Management together with Ronald Shear in 1989. Using a wide range of strategies spanning a variety of mostly liquid asset classes, Englander was able to turn the $ 35 million used to launch the fund into a Wall Street giant of over $ 45 billion. With an estimated net worth of $ 9.6 billion in 2021, it’s no wonder Wall Street’s focus is on the guru when he takes a step. With all of this in mind, we used TipRanks’ database to take a closer look at two Penny stocks that Englander recently bought. The platform found that both buy-rated tickers were also endorsed by some members of the analyst community. T2 Biosystems (TTOO) We start in the healthcare industry where T2 Biosystems is working to revolutionize diagnostics. The company offers diagnosticians and medical laboratories a range of devices based on T2MR (T2 Magnetic Resonance) technology to diagnose a wide variety of septic diseases quickly and accurately. The company notes that sepsis kills more people each year than AIDS, breast cancer and prostate cancer combined. Quick and accurate diagnosis is key to patient survival, and this is the niche that T2 seeks to fill. The company’s technology enables diagnostic blood tests with results available in a matter of hours compared to the 1 to 5 days currently required by most medical laboratory tests. Available test products include the T2Bacteria Panel and T2Candida Panel, which are the only FDA-approved blood tests for septic agents that do not have to wait for a blood culture. A T2SARS-CoV-2 panel of upper airway samples is also available. T2 has an active pipeline of rapid diagnostic tests for a wide variety of diseases. Upcoming products include the T2Cauris panel and the T2Resistance panel. These test products are currently for Research Use (ROU) only in the United States. The T2Lyme panel, which enables faster diagnosis of difficult-to-diagnose Lyme disease, is at an earlier stage of development. All T2 products work with the same T2Dx instrument and thus enable interchangeability in the laboratory environment. The device offers a simple user interface and works with only 4 ml of whole blood. T2 boasts that its device is used in more than 200 hospitals around the world. In the first quarter of 2021, T2 revenue increased 173% year over year to $ 7 million. This was due to product sales increasing 345% year over year to $ 4.7 million. US sepsis test utilization increased 85% in the quarter year over year, showing increased adoption of the device and technology. Izzy Englander is among those who have high hopes for this name in healthcare. In the first quarter, Englanders Millennium raised over 1.36 million TTOO shares valued at $ 1.5 million. This increased Englander’s stake in the company to 2.68 million shares with a market value of $ 2.9 million. Canaccord’s 5-star analyst Charles Duncan is also a fan. Duncan gives TTOO shares a buy rating along with a price target of $ 3.50. This goal conveys his confidence in TTOO’s ability to grow 212% over the next twelve months. (To see Duncan’s track record, click here.) “T2 revenue growth of + 345% year over year is a positive starting point for the company’s post-pandemic business strategy, supported by scaling to close to 10 direct sales reps in the first quarter . We view the acquisitions of Cepheid, BioFire, GenMark and Luminex as confirmation that the hospital laboratory is an attractive industry segment as clinicians (and patients) desire to move from centralized testing strategies to a more decentralized approach. With these four companies off the table, T2 should benefit from the scarcity value. Regardless, a more aggressive approach to commercial execution should go well with increasing awareness of antibiotic resistance and sepsis in a post-pandemic environment where diagnosis of infectious diseases is a priority, “noted Duncan. It turns out that other analysts have high hopes With 4 buys and a single hold, the word on the street is that this stock, currently trading at $ 1.10 each, is a strong buy, and its average target price of $ 2.83 gives upside potential 156% (see TTOO stock analysis) TipRanks) Sesen Bio (SESN) The second stock we’ll look at, Sesen Bio, is a pharmaceutical company. Sesen works in cancer treatment and develops antibody-drug conjugate therapies. The result is a single protein molecule that kills cancer cells with minimal toxic effects on the body – a complementary response from the patient ten stimulates the natural immune system. Sesen’s pipeline currently includes a drug candidate, Vicineum, which is being tested for multiple lanes at the same time. The main avenue that has completed clinical trials and initiated the Biological License Application (BLA) submission process is through the treatment of non-muscle invasive bladder cancer. The BLA was approved for filing by the FDA last February, and the company is on track for possible approval on August 18, 2021. European approval of Vicineum for the treatment of bladder cancer is expected in early 2022. The company’s other pipeline projects are earlier stages. Vicineum is currently being investigated for the treatment of head and neck cancer and is in phase 2 trials. Other traces of investigation are still in the pre-clinical stage. Clinical stage biopharmaceutical companies are always very speculative, and in this case Englander didn’t mind speculating. In the first quarter, his company bought 987,926 shares of SESN, increasing its stake in the company by 156%. Englander’s stake in Sesen now stands at $ 2.9 million. 5-star analyst Swayampakula Ramakanth, who deals with SESN for HC Wainwright, also sees an opportunity. “Given Vicineum’s favorable risk-benefit profile demonstrated in the Phase 3 VISTA trial, we believe the drug has a high likelihood of gaining regulatory approvals from the FDA and EMA. Sesen is preparing We have selected Syneos, a leading contract sales organization, as part of building and managing a 35-strong sales team to reach approximately 2,000 high-prescription BCG patients. We expect the drug to be available immediately We expect Vicineum to be risk-adjusted. Revenue of $ 516 million by 2030E increased from $ 9 million in 2021E, “said Ramakanth. Ramakanth’s comments support his buy recommendation for the stock as well as his price target of $ 8. At current valuations, this target implies an upside potential of 170% over the next 12 months. (To see Ramakanth’s track record, click here.) Sometimes the penny stocks can slip under the radar. This has only attracted two recent analyst reviews. However, both agree that this is a stock to buy, which makes the consensus on moderate buy unanimous. The shares are priced at $ 2.94 with an average target price of $ 7.50, indicating an upward movement of 155% over the coming year. (See SESN Stock Analysis on TipRanks.) To find great ideas for trading penny stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of the insights into TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.